← Leaderboards
William Ramses Bishai
Johns Hopkins University
$43,237,711
Attributed
$53,075,806
Total exposure
28
Grants
21
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $5.6M · FY2005–25$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$53,075,806 · 28
By mechanism
R01$42,037,136 · 13
R44$4,250,548 · 2
R21$3,150,233 · 7
R37$2,441,514 · 1
P30$583,588 · 2
T32$506,224 · 1
Top collaborators
- Igor Kramnik5 shared
- Smriti Mehra5 shared
- Peter David Suzdak5 shared
- Sabra L Klein3 shared
- Srinivasan Chandrasegaran2 shared
- John R. Murphy2 shared
- William Robert Jacobs1 shared
Most similar at Johns Hopkins University
Same institution · by research overlap
- Elisa Helen Ignatius$794,880
- Srinivasan Chandrasegaran$2,923,472
Others in their field
Top investigators on “Mycobacterium Tuberculosis”
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$267,251,837
- Constance Ann Benson · University Of California, San Diego$150,079,712
- Kevin Urdahl · Seattle Children'S Hospital$86,597,961
- David Alland · Rutgers Biomedical And Health Sciences$70,943,567
- Sarah Fortune · Harvard School Of Public Health$51,119,645
- William Robert Jacobs · Albert Einstein College Of Medicine$43,123,310
Research focus
Mycobacterium TuberculosisTuberculosisCellsResponseVirulenceAnimal ModelInfectionPharmaceutical PreparationsIn VitroMacrophageGranulomaMouse ModelOryctolagus CuniculusTissuesLungImmune ResponseGrowthIn VivoBasePathogenGenesImmunityCessation Of LifeDesign
Grant awards (109)
Macrophage senescence as a driver of granuloma failure and progression to necrosis in TB and TB/HIV$3,145,850
R01 · FY2025 · AI · contact PI
Esx5 secretome in TB and TB-HIV pathogenesis and immunity$820,246
R01 · FY2025 · AI
Genetic and hormonal mechanisms mediating sex differences in TB and TB-HIV$813,838
R37 · FY2025 · AI · contact PI
Immunotherapy to deplete key Treg subsets in solid tumors$706,495
R44 · FY2025 · CA
Microbiology, Immunology, Animal Modeling and Imaging$160,622
P30 · FY2025 · AI · contact PI
Immunotherapy to deplete key Treg subsets in solid tumors$1,293,505
R44 · FY2024 · CA
A STINGing vaccine for TB$1,068,965
R01 · FY2024 · AI · contact PI
Glutamine metabolism inhibitors for TB and TB-HIV: dual action as host-directed therapies with antibacterial activity$813,838
R01 · FY2024 · AI · contact PI
Targeted cell-depleting immunotherapy for TB and HIV$672,796
R01 · FY2024 · AI · contact PI
Microbiology, Immunology, Animal Modeling and Imaging$143,051
P30 · FY2024 · AI · contact PI
A STINGing vaccine for TB$1,161,477
R01 · FY2023 · AI · contact PI
Genetic and hormonal mechanisms mediating sex differences in TB and TB-HIV$813,838
R37 · FY2023 · AI · contact PI
Glutamine metabolism inhibitors for TB and TB-HIV: dual action as host-directed therapies with antibacterial activity$813,838
R01 · FY2023 · AI · contact PI
Targeted cell-depleting immunotherapy for TB and HIV$672,796
R01 · FY2023 · AI · contact PI
Microbiology, Immunology, Animal Modeling and Imaging$140,692
P30 · FY2023 · AI · contact PI
A STINGing vaccine for TB$1,051,436
R01 · FY2022 · AI · contact PI
Genetic and hormonal mechanisms mediating sex differences in TB and TB-HIV$813,838
R37 · FY2022 · AI · contact PI
Glutamine metabolism inhibitors for TB and TB-HIV: dual action as host-directed therapies with antibacterial activity$813,838
R01 · FY2022 · AI · contact PI
Treg-depleting immunotherapy$811,405
R44 · FY2022 · CA
Targeted cell-depleting immunotherapy for TB and HIV$672,796
R01 · FY2022 · AI · contact PI
Microbiology, Immunology, Animal Modeling and Imaging$139,223
P30 · FY2022 · AI · contact PI
Treg-depleting immunotherapy$1,188,595
R44 · FY2021 · CA
Glutamine metabolism inhibitors for TB and TB-HIV: dual action as host-directed therapies with antibacterial activity$813,838
R01 · FY2021 · AI · contact PI
A STINGing vaccine for TB$808,927
R01 · FY2021 · AI · contact PI
Targeted cell-depleting immunotherapy for TB and HIV$672,796
R01 · FY2021 · AI · contact PI
A STINGing vaccine for TB$842,441
R01 · FY2020 · AI · contact PI
Glutamine metabolism inhibitors for TB and TB-HIV: dual action as host-directed therapies with antibacterial activity$780,174
R01 · FY2020 · AI · contact PI
Targeted cell-depleting immunotherapy for TB and HIV$672,796
R01 · FY2020 · AI · contact PI
M.tb Survival Regulatory Genes$521,301
R01 · FY2020 · AI · contact PI
Treg-depleting immunotherapy$250,548
R44 · FY2020 · CA
PpiA, a multitasking mycobacterial virulence protein$204,688
R21 · FY2020 · AI · contact PI
Aberrant immune activation in the tuberculosis granuloma: a pivotal role in necrosis$738,628
R01 · FY2019 · HL
M.tb Survival Regulatory Genes$521,301
R01 · FY2019 · AI · contact PI
PpiA, a multitasking mycobacterial virulence protein$245,625
R21 · FY2019 · AI · contact PI
TB goes viral: Interplay between mycobacteria RNA and host cytosolic surveillance pathways$204,688
R21 · FY2019 · AI · contact PI
Targeting host immune cells and DAMP molecules to improve outcome in tuberculosis$204,687
R21 · FY2019 · AI · contact PI
Evaluation of PARP-1 as a target of host-directed therapy in tuberculosis$204,687
R21 · FY2019 · AI · contact PI
Aberrant immune activation in the tuberculosis granuloma: a pivotal role in necrosis$738,628
R01 · FY2018 · HL
M.tb Survival Regulatory Genes$521,301
R01 · FY2018 · AI · contact PI
TB goes viral: Interplay between mycobacteria RNA and host cytosolic surveillance pathways$245,594
R21 · FY2018 · AI · contact PI
How do lysosomal disorders drive susceptibility to M.tb?$245,594
R21 · FY2018 · AI · contact PI
Evaluation of PARP-1 as a target of host-directed therapy in tuberculosis$245,563
R21 · FY2018 · AI · contact PI
Targeting host immune cells and DAMP molecules to improve outcome in tuberculosis$245,438
R21 · FY2018 · AI · contact PI
Inhibition of matrix degrading enzymes to limit cavitation in tuberculosis$204,662
R21 · FY2018 · AI · contact PI
Targeted Immunotherapy for Tuberculosis and HIV co-infection$204,558
R21 · FY2018 · AI · contact PI
Aberrant immune activation in the tuberculosis granuloma: a pivotal role in necrosis$737,411
R01 · FY2017 · HL
M.tb Survival Regulatory Genes$521,301
R01 · FY2017 · AI · contact PI
Inhibition of matrix degrading enzymes to limit cavitation in tuberculosis$245,188
R21 · FY2017 · AI · contact PI
Targeted Immunotherapy for Tuberculosis and HIV co-infection$244,938
R21 · FY2017 · AI · contact PI
How do lysosomal disorders drive susceptibility to M.tb?$204,323
R21 · FY2017 · AI · contact PI
Aberrant immune activation in the tuberculosis granuloma: a pivotal role in necrosis$753,536
R01 · FY2016 · HL
M.tb Survival Regulatory Genes$521,301
R01 · FY2016 · AI · contact PI
Biomarkers and Signaling in Tuberculosis$613,683
R01 · FY2014 · AI · contact PI
Gene regulation and virulence in TB$452,897
R01 · FY2014 · AI · contact PI
Biomarkers and Signaling in Tuberculosis$576,862
R01 · FY2013 · AI · contact PI
M.tb Survival Regulatory Genes$439,781
R01 · FY2013 · AI · contact PI
Gene regulation and virulence in TB$425,724
R01 · FY2013 · AI · contact PI
Biomarkers and Signaling in Tuberculosis$613,683
R01 · FY2012 · AI · contact PI
M.tb Survival Regulatory Genes$457,542
R01 · FY2012 · AI · contact PI
Gene regulation and virulence in TB$452,897
R01 · FY2012 · AI · contact PI
PK/PD Evaluation Resistance Development in Caseating Granuloma$646,181
R01 · FY2011 · AI · contact PI
Biomarkers and Signaling in Tuberculosis$637,548
R01 · FY2011 · AI · contact PI
M.tb Survival Regulatory Genes$454,875
R01 · FY2011 · AI · contact PI
Gene regulation and virulence in TB$453,078
R01 · FY2011 · AI · contact PI
Screen for synthetic lethality in Mycobacterium tuberculosis$40,590
R03 · FY2011 · MH · contact PI
PK/PD Evaluation Resistance Development in Caseating Granuloma$645,971
R01 · FY2010 · AI · contact PI
Gene regulation and virulence in TB$457,640
R01 · FY2010 · AI · contact PI
M.tb Survival Regulatory Genes$457,640
R01 · FY2010 · AI · contact PI
Gene Regulation and Virulence in TB and MAC$238,048
R01 · FY2010 · AI · contact PI
Screen for synthetic lethality in Mycobacterium tuberculosis$41,000
R03 · FY2010 · MH · contact PI
PK/PD Evaluation Resistance Development in Caseating Granuloma$633,491
R01 · FY2009 · AI · contact PI
Gene Regulation and Virulence in TB and MAC$381,367
R01 · FY2009 · AI · contact PI
PK/PD Evaluation Resistance Development in Caseating Granuloma$615,040
R01 · FY2008 · AI · contact PI
Gene Regulation and Virulence in TB and MAC$381,367
R01 · FY2008 · AI · contact PI
Mycobacterium tuberculosis Survival Regulatory Genes$380,205
R01 · FY2008 · AI · contact PI
Screen for Synthetic Lethality in Mycobacterium Tuberculosis$24,973
R03 · FY2008 · MH · contact PI
Gene Regulation and Virulence in TB and MAC$388,062
R01 · FY2007 · AI · contact PI
Mycobacterium tuberculosis Survival Regulatory Genes$387,569
R01 · FY2007 · AI · contact PI
Toolbox for Tuberculosis Drug Development$387,569
R01 · FY2007 · AI · contact PI
Toolbox for Tuberculosis Drug Development$399,144
R01 · FY2006 · AI · contact PI
M. tb. Survival Regulatory Genes$399,144
R01 · FY2006 · AI · contact PI
Gene Regulation and Virulence in TB and MAC$398,433
R01 · FY2006 · AI · contact PI
Toolbox for Tuberculosis Drug Development$408,750
R01 · FY2005 · AI
M. tb. Survival Regulatory Genes$408,750
R01 · FY2005 · AI
Gene Regulation and Virulence in TB and MAC$399,621
R01 · FY2005 · AI
Cell Division Control and Virulence in Mycobacteria$336,125
R01 · FY2005 · AI
Multidisciplinary Training in Tuberculosis$55,803
T32 · FY2005 · AI
Toolbox for Tuberculosis Drug Development$408,750
R01 · FY2004 · AI
M. tb. Survival Regulatory Genes$408,750
R01 · FY2004 · AI
Cell Division Control and Virulence in Mycobacteria$336,125
R01 · FY2004 · AI
Multidisciplinary Training in Tuberculosis$115,499
T32 · FY2004 · AI
GENE REGULATION AND VIRULENCE IN TB AND MAC$337,457
R01 · FY2003 · AI
Cell Division Control and Virulence in Mycobacteria$336,125
R01 · FY2003 · AI
Toolbox for Tuberculosis Drug Development$204,375
R01 · FY2003 · AI
Multidisciplinary Training in Tuberculosis$116,041
T32 · FY2003 · AI
LATENCY AND REACTIVATION TUBERCULOSIS$456,056
R01 · FY2002 · HL
Cell Division Control and Virulence in Mycobacteria$361,125
R01 · FY2002 · AI
GENE REGULATION AND VIRULENCE IN TB AND MAC$328,691
R01 · FY2002 · AI
RATIONAL DRUG DISCOVERY FOR MAC AND M TB$306,611
R01 · FY2002 · AI
Multidisciplinary Training in Tuberculosis$116,415
T32 · FY2002 · AI
RATIONAL DRUG DISCOVERY FOR MAC AND M TB$372,288
R01 · FY2001 · AI
Cell Division Control and Virulence in Mycobacteria$325,013
R01 · FY2001 · AI
M TB SURVIVAL REGULATORY GENES$308,012
R01 · FY2001 · AI
GENE REGULATION AND VIRULENCE IN TB AND MAC$283,762
R01 · FY2001 · AI
Multidisciplinary Training in Tuberculosis$102,466
T32 · FY2001 · AI
GENE REGULATION AND VIRULENCE IN TB AND MAC$38,539
R01 · FY2001 · AI
M TB SURVIVAL REGULATORY GENES$458,635
R01 · FY2000 · AI
RATIONAL DRUG DISCOVERY FOR MAC AND M TB$289,010
R01 · FY2000 · AI
GENE REGULATION AND VIRULENCE IN TB AND MAC$275,569
R01 · FY2000 · AI